# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2016 Earnings Results

**Report date:** 2017-02-09 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2016

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.91%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.04 | N/A | +21.36% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their product pipeline and future growth. They acknowledged challenges but remain committed to innovation.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They emphasized ongoing investment in research and development.

> The team remains focused on long-term growth despite current market conditions.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates better-than-expected profitability, which likely contributed to the positive stock reaction of 1.91%. Investors may view the earnings beat as a sign of resilience in the company's operations. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2016_